Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. - Wikidata - wikimedia - TriplyDB

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

http://www.wikidata.org/entity/Q34369159

about

Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma The future of biologic agents in the treatment of Sjögren's syndrome Rituximab in the treatment of inflammatory myopathies: a review Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels.Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia Identification of global transcriptional dynamics Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab Advances in the use of biologic agents for the treatment of systemic vasculitis Cytokine modulators in the treatment of sarcoidosis.Preclinical validation of salivary biomarkers for primary Sjögren's syndrome Rituximab in primary Sjögren's syndrome: a ten-year journey.Novel aspects of Sjögren's syndrome in 2012.Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Clinical uses of intravenous immunoglobulin.Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.The management of Sjögren's syndrome.Emerging drug therapies for systemic lupus erythematosus.B lymphocytes as therapeutic targets in systemic lupus erythematosus.Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder.Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice.Biologic treatments for systemic rheumatic diseases Ofatumumab treatment in lupus nephritis patients.Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis Primary Sjogren's syndrome: too dry and too tired.Update on emerging drug therapies for systemic lupus erythematosus.

P2860

Q24644580-CECA1FF4-154E-43AB-A801-3D3BFFA219A1 Q24681044-7D09BEDE-A3AE-4C2B-9E4A-6180849A4E8E Q28077745-E417E10D-E8BC-4E5F-94B8-A306EA8982E0 Q31087724-88CC142D-69E2-47E8-9867-5B780A825216 Q33372523-8CA07BF2-5FBD-4343-923E-46BD0EC8068A Q33421190-91BC51CF-7B44-46CD-B9BB-BFDDC677805F Q33481016-7F97C416-87FD-4758-A91E-0EC5416F43EF Q33741009-FEB8B308-B7D0-4EB3-9ABC-75966FCE172C Q34065598-65B96A7B-71A6-48A8-A93E-80EA433F835C Q34190083-712B57BC-F729-470D-8084-1DABD7B55644 Q34370333-A08BAC9C-7135-4260-B7FC-5031A25E39A2 Q34432465-ED880AAA-CB7F-460B-B389-AAAC7698F60B Q34650103-49E63278-8F6B-4857-80ED-AE8196909AE1 Q34897189-F79A866F-8DC7-40E4-B893-E95E4FDDC703 Q35021812-735ECFFE-A421-4CFC-B952-926AAAB7B9A6 Q35605535-6C4EE737-90C3-4ACA-B054-A0C69A2CF317 Q35638200-5815B4CA-0E7F-40CB-B6D9-598E619AB15C Q35953330-C8681B6B-870C-4F8B-AABC-FC27A199F8E2 Q36168964-5519EBF3-2DFE-4075-9C73-19ACE6FE8411 Q36171750-98B93233-91C9-4FF0-B316-D3A4A66CA69E Q36264883-C25D3D39-F730-4674-954B-339481BAA8DA Q36460981-F2B3B672-208E-41A2-9834-F9CF5FECEAFB Q36504479-BEEDDF62-5729-4C8A-BF41-6B46504405D6 Q36577391-D18AF8B4-625B-4E32-8668-31415F7D878C Q36577478-0A01E289-191D-49A0-97D7-B85BEBF25151 Q36634248-620DB86B-1844-4192-BA40-4369FB75919C Q36653646-C423BF1C-9FEE-4F7F-B276-280ADD7B0564 Q36696574-030C8003-FAA7-4E07-A967-52B825FB6CC9 Q36798703-A17CCA93-BE5B-4977-ABD0-6F43641FC410 Q36886291-44A352C7-3F02-4851-A157-02BBD6DC0F6A Q36897408-EBD4A75E-2500-4484-9FCF-10DA8A12BF7D Q37072796-96B15D9D-6784-42DC-857D-3CA71AC1BA36 Q37087438-C82C076E-F3A9-4AC5-BC88-A1B009ECF8D2 Q37119045-DD1A6B8C-E5D3-4114-84E6-474BA53385B1 Q37123206-DA99F47D-9B80-4786-AD9F-72DCB477D762 Q37290665-50D9813E-38F6-4513-8776-03B132013A13 Q37541561-B3F2A33C-37C2-4FB9-BF64-9EAC72E453A1 Q37640836-2B46600E-3D81-46FB-BE51-8F42933F6608 Q37690497-2950691D-4A90-45E0-BD40-72BE96C2DC2B Q37690745-21A83E72-5519-4D64-A496-D72DC17210C4

P2860

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

http://www.wikidata.org/entity/Q34369159

description

2004 nî lūn-bûn

@nan

2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Tolerance and short term effic ...... systemic autoimmune diseases.

@ast

Tolerance and short term effic ...... systemic autoimmune diseases.

@en

Tolerance and short term effic ...... systemic autoimmune diseases.

@nl

type

label

Tolerance and short term effic ...... systemic autoimmune diseases.

@ast

Tolerance and short term effic ...... systemic autoimmune diseases.

@en

Tolerance and short term effic ...... systemic autoimmune diseases.

@nl

prefLabel

Tolerance and short term effic ...... systemic autoimmune diseases.

@ast

Tolerance and short term effic ...... systemic autoimmune diseases.

@en

Tolerance and short term effic ...... systemic autoimmune diseases.

@nl

P1433

Q34369159-E7B1412E-3043-4317-8A9F-5B22DFFF5F32

P1476

Q34369159-1DEC88DC-02C7-4525-8E55-89299FC7D99C

P2093

Q34369159-0F37907F-412A-4F09-892B-10FCC82D07CA

Q34369159-0F98E825-4931-4995-A2A4-BE359D8D0B50

Q34369159-12545714-0E14-452C-B5BF-795840F0209E

Q34369159-14B6F6C2-9EE8-43F2-B931-E77B2FFB7008

Q34369159-28997779-4AAA-4D76-A176-85E3D340635B

Q34369159-399B7AFB-CCFF-47D3-B79B-8D429F6CB099

Q34369159-3E0C05B1-7B8D-4312-B2CE-134C64505730

Q34369159-3F9C87F0-3413-4C66-BCD7-B3A221F2C2D0

Q34369159-75D88443-0652-421D-8AA5-9BB0B3992AE8

Q34369159-7BAD0D76-FAAE-4A53-9062-B5C63DD95BAC

P2860

Q34369159-189A4B03-DF0C-435C-B017-8C1E90197019

Q34369159-2F07233A-8A95-4659-8F11-9734FF6031B5

Q34369159-35A72F9A-3052-4B61-8F50-50FD77786BCD

Q34369159-4675D07A-1AF2-42EF-BD5D-FDA1DF971EF4

Q34369159-66A2BA32-3374-4890-9175-33E466CD25EB

Q34369159-6A05D90C-108A-415C-B2B9-8DFEF53E29CC

Q34369159-9213EE24-B1B1-4BE4-B042-B533EBC36BA7

Q34369159-BC27A1E4-B5A6-4F4D-A3AD-3F4952745E18

P304

Q34369159-2B22D136-24C7-4008-8D5B-C04485D637DB

P31

Q34369159-27B34A4D-EF2C-4C67-8B84-AF63F601D1BD

P356

Q34369159-B2FF609D-2402-4885-931B-3DF8F46D621B

P407

Q34369159-A6B58BB7-6160-4263-A9A1-6A857C27908F

P433

Q34369159-6D222F2C-7942-447E-9417-D106C86C308A

P478

Q34369159-33DD3B6D-0140-4834-9DDA-1E06287FB3BF

P50

Q34369159-8CAE3BA9-4D70-4CEE-922C-18774C9C9EA2

P577

Q34369159-A7F9AF15-AE75-4BEF-84D7-A19F10E8EF06

P5875

Q34369159-11F80110-2C79-4D2F-A6C6-B02424EE5380

P698

Q34369159-14A24F5B-4ABD-4311-BB3D-B25777174F40

P921

Q34369159-5BBE3A76-7F14-4612-B402-C8F811AE9A64

P932

Q34369159-52730DD8-FDE2-45AB-B938-2BCFD0FFE88E

P356

ARD.2004.029694

P1433

Annals of the Rheumatic Diseases

P1476

Tolerance and short term effic ...... systemic autoimmune diseases.

@en

P2093

A Cantagrel

http://www.w3.org/2001/XMLSchema#string

B Combe

http://www.w3.org/2001/XMLSchema#string

B Moura

http://www.w3.org/2001/XMLSchema#string

C Larroche

http://www.w3.org/2001/XMLSchema#string

C Masson

http://www.w3.org/2001/XMLSchema#string

Club Rheumatismes et Inflammation (CRI)

http://www.w3.org/2001/XMLSchema#string

D Farge

http://www.w3.org/2001/XMLSchema#string

D Wendling

http://www.w3.org/2001/XMLSchema#string

J Sibilia

http://www.w3.org/2001/XMLSchema#string

J-E Gottenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.

An open study of B lymphocyte depletion in systemic lupus erythematosus.

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.

Rituximab for the treatment of type II mixed cryoglobulinemia

P304

913-920

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2004.029694

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Juan-Manuel Anaya

P577

2004-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8175857

http://www.w3.org/2001/XMLSchema#string

P698

15550531

http://www.w3.org/2001/XMLSchema#string

P921

P932

1755517

http://www.w3.org/2001/XMLSchema#string